Rescue Promising Programs by Applying Selexis Technologies to Difficult-to-Express Proteins
April 13, 2019
Solutions for complex human diseases are being addressed with increasingly complex protein therapeutic modalities. These include molecules such as bispecific proteins, DARPins, triabodies and novel scaffolds decorated with peptides, enzymes or growth factors, to name a few. Many, if not most, of these proteins do...
Learn More
Selexis SUREtechnology Platform
April 13, 2019
The Selexis SURE CHO-M Cell Line is a proprietary high-performance mammalian cell line that is derived from CHO-K1 cells and used for the production of therapeutic recombinant proteins and monoclonal antibodies. The growth and production properties of the Selexis SURE CHO-M Cell Line are well...
Learn More
Research Cell Bank Development
April 13, 2019
For nearly 20 years, Selexis has been helping its partners predictably, rapidly and cost-effectively generate life-saving biologic medicines and vaccines. Its SUREtechnology Platform™ is being used by  clients worldwide, resulting in more than 119 biologic drug products in clinical and commercial manufacturing. Selexis is able...
Learn More